Lexaria Bioscience trumpets its slate of DehydraTECH licensing agreements

() (OTCMKTS:LXRP) has signed eleven licensing agreements for its DehydraTECH drug absorption platform thus far in 2019, the company told shareholders Tuesday.

Broadly, DehydraTECH helps nutrients and pharmaceutical ingredients get absorbed faster and more effectively by the body.

Lexaria’s licensees are using it to create things like cannabis edibles, CBD beverages and oral nicotine products.

For instance, Lexaria is working with Hill Street Beverage Company Inc () using DehydraTECH to create THC and CBD powder, and Altria Ventures is targeting a reduced-risk oral nicotine option.

READ: Lexaria Bioscience, Hill Street Beverage sign 10-year joint manufacturing partnership for DehydraTec products

All told, Lexaria has 9 corporate licensees with 11 licensing agreements developing unique products.

CEO Chris Bunka said: "The first half of 2019 delivered a period of unprecedented achievements for Lexaria. We signed more license agreements than ever before in our company’s history, many of which were larger in scope than anything previous.”

The company expects explosive revenue growth as its client commence operations beginning in late 2019. It expects new licensing agreements to continue rolling in as demand for DehydraTECH continues.

There’s promising data to pair with that confidence. In one previously announced animal study, Lexaria’s formations delivered 20 times more CBD into brain tissue and achieved peak blood levels of nine times greater than generic industry formations.

The company's stock fell 3.4% Tuesday to C$0.86 on the CSE and 6.5% to US$0.65 on OTC Markets.

Contact Andrew Kessel at [email protected]

Follow him on @andrew_kessel